Abstract
Mast cell tumors (MCTs) are hematopoietic neoplasms composed of mast cells. It is highly common in dogs and is extremely important in the veterinary oncology field. It represents the third most common tumor subtype, and is the most common malignant skin tumor in dogs, corresponding to 11% of skin cancer cases. The objective of this critical review was to present the report of the 2nd Consensus meeting on the Diagnosis, Prognosis, and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors, which was organized by the Brazilian Association of Veterinary Oncology (ABROVET) in August 2021. The most recent information on cutaneous and subcutaneous mast cell tumors in dogs is presented and discussed.
Highlights
Several epidemiological studies from many countries point out that mast cell tumors (MCTs) have a high frequency in dogs, and is important in veterinary oncology
Other forms of dissemination related to Mast cell tumors (MCTs) are mastocythemia, and mast cell leukemia
The World Health Organization (WHO) proposed a clinical staging system (Table 1) for canine MCT, which classifies dogs with the presence of stage II lymph node metastasis and dogs with the presence of multiple tumors as stage III, even with lymph nodes free from metastasis
Summary
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have